search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


QUality of life after Embolization vs. hySTerectomy in Adenomyosis.


- candidate number23982
- NTR NumberNTR5615
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR17-feb-2016
- Secondary IDsNL52652.029.15 METC VUMC
- Public TitleQUality of life after Embolization vs. hySTerectomy in Adenomyosis.
- Scientific TitleUterine artery embolization versus hysterectomy for symptomatic adenomyosis:a randomized controlled trial.
- ACRONYMQUESTA trial: QUality of life after Embolization vs. hySTerectomy in Adenomyosis.
- hypothesisThis study aims to evaluate the impact of UAE on Quality of life (QOL) in comparison to hysterectomy in adenomyosis patients.
- Healt Condition(s) or Problem(s) studiedAdenomyosis
- Inclusion criteria Premenopausal women with MRI confirmed symptomatic adenomyosis or dominant adenomyosis in combination with fibroids.
Premenopausal women with an indication for hysterectomy.
No wish to conceive in the present or future
Able to understand Dutch language.
- Exclusion criteria Younger than 18 years of age
Pelvic infection/Suspicion or presence of malignancy
Current pregnancy
Contra-indication for angiography (such as contrast fluid allergy, coagulopathy and renal failure), when not treatable
Deep infiltrating endometriosis requiring surgery or with risks on intestinal stenosis
Concurrent removable submucous fibroids (Patients eligible after removal)
- mec approval receivedyes
- multicenter trialyes
- randomisedyes
- masking/blindingNone
- controlActive
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 17-nov-2015
- planned closingdate1-nov-2018
- Target number of participants96
- InterventionsUterine artery embolization -> experimental treatment
Hysterectomy -> standard care
Randomization in 2:1 ratio (embolisation 2 versus hysterectomy 1)
- Primary outcome Quality of life:
To demonstrate non inferiority of treatment of adenomyosis with uterine artery embolization compared to treatment by hysterectomy in terms of quality of life at 26, 52 and 104 weeks after treatment (measured by WHOQOL-Bref and SF-12)
- Secondary outcomeThe two treatments will also be compared in terms of:
Clinical outcomes (PBAC, NRS 0-100 scale, Facet 1:Pain and discomfort WHOQOL-100, Satisfaction with allocated treatment (likert-scale), patient preference)
Recovery related outcomes (RI-10)
Quality of life outcomes (HOQOL-Bref and SF-12)
Cost outcomes (EQ-5D)
Imaging outcomes (uterine size reduction, infarction rate, junctional zone reduction, concomitant fibroids)
- TimepointsMeasurements: will be taken at baseline and 6, 12, 26, 52 and 104 weeks after therapy.
- Trial web sitewww.questa-studie.nl
- statusopen: patient inclusion
- CONTACT FOR PUBLIC QUERIES Annefleur de Bruijn
- CONTACT for SCIENTIFIC QUERIESDr W.J.K. Hehenkamp
- Sponsor/Initiator VU University Medical Center
- Funding
(Source(s) of Monetary or Material Support)
Celenova
- Publications
- Brief summaryAdenomyosis is defined as the benign invasion of endometrial stroma and glands in the myometrium, surrounded by hypertrophic and hyperplastic myometrium. Hysterectomy is established as the final treatment option when conservative treatment fails. Case series for UAE (uterine artery embolization) in adenomyosis patients show promising results. However, a randomized controlled trial is lacking.

Objective of the study:
This study aims to evaluate the impact of UAE on Quality of life (QOL) in comparison to hysterectomy in adenomyosis patients. A cost-effectiveness study will be part of the trial as well as a cohort hysterectomy group to clearify imaging and diagnosis of adenomyosis.

Study design:
Non-blinded randomized controlled trial and cohort alongside the trial.

Study population:
Premenopausal women without the desire to conceive and who have symptomatic MRI confirmed pure adenomyosis or dominant adenomyosis in combination with fibroids. (If the deep fibroids are clearly less to the extent of adenomyosis in terms of volume we consider it dominant adenomyosis)

Intervention (if applicable):
UAE, performed by experienced interventional radiologists versus hysterectomy (laparoscopically, abdominally or vaginally).

Primary study parameters/outcome of the study:
Primary endpoint: quality of life as measured by a combination of the World Health Organization Quality-of-Life Scale (WHOQOL-Bref) and short-form-12 (SF-12) questionnaire at 26 weeks after therapy.

Secundary study parameters/outcome of the study (if applicable):
The two treatments will also be compared in terms of Clinical outcomes, Recovery related outcomes, Quality of life outcomes and cost outcomes. Also imaging outcomes will be investigated at baseline in order to identify potential predictive parameters for therapy effect.
- Main changes (audit trail)
- RECORD17-feb-2016 - 18-feb-2016


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl